A Pilot Study Assessing the Ability of 5-Aminosalicylic Acid to Modulate the Immune Response in Chronic Beryllium Disease.
- Authors:
- Brian J Day,
- Jie Huang,
- Briana Q Barkes,
- May Gillespie,
- Li Li,
- Lisa A Maier
Ann Am Thorac Soc 2018 Apr;15(Supplement_2):S133
1 Division of Environmental and Occupational Health Sciences, Hollis Laboratory, Department of Medicine, National Jewish Health, Denver, Colorado; and.
Chronic beryllium disease is a granulomatous lung disease, characterized by the accumulation of macrophages and beryllium-specific CD4 T-cells that proliferate and produce T-helper cell type 1 cytokines. Previous studies indicate that beryllium-mediated oxidative stress enhances cytokine response in chronic beryllium disease CD4 T-cells. 5-Aminosalicylic acid (5-ASA) is currently used to treat inflammatory bowel disease and has both antioxidant and antiinflammatory actions. Read More
